Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Silo Pharma, Inc. - Common Stock
(NQ:
SILO
)
0.4373
-0.0929 (-17.52%)
Streaming Delayed Price
Updated: 3:44 PM EDT, Apr 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Silo Pharma, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
September 20, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
↗
September 18, 2023
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Via
Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
↗
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Begin Feasibility Study of Proprietary Novel Intranasal Formulation for PTSD
September 12, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
September 12, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
↗
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
↗
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via
Benzinga
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
↗
August 28, 2023
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
↗
August 28, 2023
Via
Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
↗
August 21, 2023
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Via
Benzinga
Topics
Cannabis
Economy
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
↗
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Strategic Engagement to Step up IP and Patent Expansion Efforts
August 10, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
August 10, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment
↗
August 08, 2023
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug...
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Significant Development Advancement of SPC-15
August 08, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
August 08, 2023
Via
Benzinga
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
August 08, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
↗
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...
Via
Benzinga
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
↗
July 28, 2023
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
↗
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers
June 23, 2023
Via
Investor Brand Network
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
June 23, 2023
Via
ACCESSWIRE
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
↗
June 22, 2023
This month, Silo Pharma (NASDAQ: SILO) announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia an
Via
Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease
June 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Revolutionizing Rheumatoid Arthritis Treatment: Psychedelics Biotech Co. Touts New Patent
↗
June 21, 2023
Psychedelics-focused biopharmaceutical company Silo Pharma, Inc. (NASDAQ: SILO) announced on Wednesday that the U.S. Patent and Trademark Office has issued Patent 16/825,371 titled "Peptide-Targeted...
Via
Benzinga
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
June 21, 2023
New patent expands Company’s intellectual property and technology rights portfolio
From
Silo Pharma, Inc.
Via
GlobeNewswire
Why Advanced Health Intelligence Shares Are Trading Higher By 111%; Here Are 20 Stocks Moving Premarket
↗
June 21, 2023
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares gained 110.8% to $1.56 in pre-market trading after the company signed a Letter of Intention with UAE-Based e-script medicine management...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
June 21, 2023
It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Wednesday morning!
Via
InvestorPlace
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
↗
June 13, 2023
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with...
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Entry into Ketamine Implant Therapeutic Research Project
June 13, 2023
Via
Investor Brand Network
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.